Agios Pharm is a biotechnology business based in the US. Agios Pharm shares (AGIO) are listed on the NASDAQ and all prices are listed in US Dollars. Agios Pharm employs 383 staff and has a trailing 12-month revenue of around $31.3 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $43.28 |
|---|---|
| 52-week range | $19.80 - $50.35 |
| 50-day moving average | $45.21 |
| 200-day moving average | $33.13 |
| Wall St. target price | $56.00 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-6.50 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $43.28 from 2024-09-06
| 1 week (2024-08-30) | -5.73% |
|---|---|
| 1 month (2024-08-09) | -0.96% |
| 3 months (2024-06-07) | -9.09% |
| 6 months (2024-03-08) | 38.32% |
| 1 year (2023-09-08) | 65.76% |
|---|---|
| 2 years (2022-09-09) | 26.77% |
| 3 years (2021-09-09) | 45.19 |
| 5 years (2019-09-09) | 29.19% |
| Revenue TTM | $31.3 million |
|---|---|
| Gross profit TTM | $12.5 million |
| Return on assets TTM | -27.25% |
| Return on equity TTM | -44.92% |
| Profit margin | 0% |
| Book value | $11.61 |
| Market Capitalization | $2.6 billion |
TTM: trailing 12 months
We're not expecting Agios Pharm to pay a dividend over the next 12 months.
Over the last 12 months, Agios Pharm's shares have ranged in value from as little as $19.795 up to $50.35. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Agios Pharm's is 0.749. This would suggest that Agios Pharm's shares are less volatile than average (for this exchange).
Agios Pharmaceuticals, Inc. , a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Use this calculator to quickly see potential outcomes of your options trades.
SoFi, Robinhood, Tastytrade, Webull, Interactive Brokers, E*TRADE, eToro and others top our list for the best options trading platforms.
A covered call is an options trading strategy that allows you to generate income from stocks you already own.
A look at GSD Capital’s highlights, limitations, fees and investment strategies.
Explore the best bonuses for opening a new brokerage account.
Looking for a discount broker like E*TRADE that offers something different? Here are some of the top alternatives to consider.
Charles Schwab and Fidelity are two powerhouse trading platforms for beginner and advanced investors.
Interactive Brokers has advanced charting tools but a high net requirement to qualify.
Discover the top tech stocks poised to lead innovation and offer substantial growth opportunities.
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.